
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc is experiencing an optimistic outlook due to heightened confidence in its lead product, KYV-101, which shows promising durability and effectiveness in treating myasthenia gravis (MG) and other autoimmune diseases. The probability of approval for KYV-101 in MG has been raised significantly, reflecting the strong initial responses observed in compassionate-use patients and a favorable safety profile. Additionally, the company has received favorable comparisons to existing therapies, with KYV-101 outperforming rituximab in randomized cohorts, reinforcing its potential as a leading candidate in the CAR-T therapy space for immunology and inflammation (I&I).
Bears say
Kyverna Therapeutics Inc faces significant challenges regarding the durability of responses for its product candidate, KYV-101, in lupus nephritis (LN) and myasthenia gravis (MG), raising concerns about the long-term efficacy of the treatment as the dataset matures. The company may also encounter difficulties in generating positive clinical data for its second product, KYV-101, in seropositive systemic disease (SPS), which could adversely impact its therapeutic portfolio. Additionally, potential long-term dilution risks pose a financial threat, further contributing to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares